Liver cancer roadmap links tumor hallmarks to treatment, including targetable mutations Mount Sinai researchers have published a landmark review defining the “hallmarks of liver cancer,” providing a comprehensive framework that connects the fundamental biological characteristics of hepatocellular carcinoma (HCC) to actionable treatment strategies, including therapies targeting specific genetic mutations. This work, published in a leading scientific journal, synthesizes over two decades of research to clarify how core cancer traits—such as sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, and genomic instability—drive liver cancer progression and inform precision medicine approaches. The review emphasizes that understanding these hallmarks is critical for identifying patients who may benefit from targeted therapies. For instance, alterations in genes such as TP53, CTNNB1, and AXIN1, which are frequently observed in HCC, directly impact key hallmarks like genome maintenance and Wnt signaling activation. These molecular changes not only serve as diagnostic markers but too represent potential therapeutic targets. The authors note that integrating molecular profiling into clinical practice allows for the selection of patients most likely to respond to treatments such as tyrosine kinase inhibitors or immune checkpoint inhibitors, particularly when combined with locoregional therapies. The study highlights how tumor microenvironment interactions—including immune evasion and angiogenesis—contribute to disease progression and resistance to therapy. By mapping these processes to established hallmarks, researchers aim to improve patient stratification and guide the development of combination strategies that address multiple cancer traits simultaneously. The review underscores that while surgical resection and transplantation remain curative options for early-stage disease, advanced HCC increasingly relies on systemic therapies guided by molecular insights. The researchers advocate for the routine use of multi-omic analyses—combining genomics, transcriptomics, and proteomics—to uncover actionable alterations and monitor tumor evolution during treatment. They also call for increased access to molecular testing in diverse populations to ensure equitable application of precision oncology approaches. This hallmarks-based framework aims to transform liver cancer care by moving beyond histology-driven classification toward biologically informed, personalized treatment plans.
Related reading